AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33726828
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (200 mg ER, Unicontin-E) once daily for 52 weeks
Trial: 33726828
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (200 mg ER, Unicontin-E)
Trial: 36857968
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg/d) and Quercetin (1250 mg/d), three consecutive days per week for three weeks
Trial: 34709013
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block with 20 mL of ropivacaine 0.5%
Trial: 32734847
Drug: Inoculated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculated with 20 μl of spore suspension (10^4 conidia per ml) from a 21-day-old PDA culture.
Trial: 36257876
Drug: Bursitis label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bursitis label plus treatment recommendation
Trial: 36257876
Drug: Rotator cuff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotator cuff tear label plus treatment recommendation
Trial: 36257876
Drug: Treatment recommendation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment recommendation
Trial: 34409858
Drug: Balstilimab in
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balstilimab in combination with zalifrelimab
Trial: 33232912
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil supplementation (400 mg EPA and DHA for 3 months, then 800 mg EPA and DHA for 9 months)
Trial: 36349244
Drug: E-OJ-01 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-OJ-01 (400 mg/day for 8 weeks)
Trial: 32903142
Drug: Same-day administration
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day administration of pegfilgrastim
Trial: 35040594
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily nasal irrigation with Johnson and Johnson's Baby Shampoo (J&J) in hypertonic saline
Trial: 35687807
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) components (problem solving, changing unhelpful thoughts, relaxation skills)
Trial: 35687807
Drug: Barriers (being
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers (being bullied, difficulty applying therapy content to new situations)
Trial: 33755143
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg daily for 48 weeks
Trial: 32692386
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (25 µg titrated to aim for serum thyrotropin levels between 0.4 and 2.5 mU/L)
Trial: 32873953
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3, 1.68 g)
Trial: 34916444
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Lycium barbarum polysaccharide (LBP) for 6 weeks
Trial: 32165040
Drug: Chemotherapy at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy at Ben Taub Hospital (BTH)
Trial: 32799841
Drug: Peripheral intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral intravenous parenteral nutrition (P-PN)
Trial: 35738551
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + a-PDT (methylene blue mediated antimicrobial photodynamic therapy using 660 nm diode laser)
Trial: 35791455
Drug: Dexmedetomidine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 5.0 mcg
Trial: 35791455
Drug: Dexmedetomidine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 7.5 mcg
Trial: 35791455
Drug: Dexmedetomidine 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 10.0 mcg
Trial: 33151775
Drug: Intravenous ascorbate
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbate (VitC) 2g
Trial: 35127522
Drug: High OC/OL‐EVOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High OC/OL‐EVOO (40 ml/day, 416 mg/Kg OC and 284 mg/kg OL for 3 months)
Trial: 35127522
Drug: High OC/OL‐EVOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High OC/OL‐EVOO (40 ml/day for 6 months)
Trial: 35127522
Drug: Low OC/OL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low OC/OL (40 ml/day, 82 mg/kg OC and 33 mg/kg OL for 3 months)
Trial: 35229548
Drug: Pomegranate peel
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate peel extract (PoPEx) 250 mg twice daily
Trial: 35229548
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily
Trial: 33616555
Drug: 0.85% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.85% saline solution for 20 minutes (control)
Trial: 33616555
Drug: Brush immersion
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush immersion in solutions (SH, Efferdent, RC)
Trial: 34156129
Drug: Milk thistle
RxNorm normalized name: MILK THISTLE
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk thistle meal (30 g/kg)
Trial: 34156129
Drug: Poultry oil
RxNorm normalized name: Cocci-Cure P for Poultry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poultry oil and milk thistle meal (30 g/kg)
Trial: 34289823
Drug: Nintedanib 50-150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 50-150 mg BID
Trial: 36247420
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg a day on top of antidiabetic treatment)
Trial: 36247420
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg a day)
Trial: 32306085
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of balneotherapy (daily whirlpool baths, hydrokinesitherapy sessions, knee shower/massages)
Trial: 32306085
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual analgesia medication only)
Trial: 35333744
Drug: Alfaxalone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (5 mg/kg)
Trial: 35333744
Drug: Alfaxalone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (5 mg/kg) and midazolam (0.5 mg/kg)
Trial: 37315099
Drug: Intolerance-of-uncertainty therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intolerance-of-uncertainty therapy (IUT)
Trial: 34134024
Drug: ReVeRe.D (iPad-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReVeRe.D (iPad-administered cognitive test battery)
Trial: 34134024
Drug: examiner-administered tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: examiner-administered tests
Trial: 33081705
Drug: Telehealth Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Trial: 34550483
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles
Trial: 34550483
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and cisplatin combination
Trial: 32319955
Drug: Paper-and-pencil followed
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil followed by tablet app
Trial: 32319955
Drug: Tablet only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet only
Trial: 35139812
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of Ranibizumab (IVR) 1 or 3 days before vitrectomy
Trial: 35139812
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of Ranibizumab (IVR) 3 days before vitrectomy
Trial: 35139812
Drug: Sham subconjunctival
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham subconjunctival injection 3 days before surgery
Trial: 35733997
Drug: MET (metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET (metformin therapy)
Trial: 32503663
Drug: Inhaled sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled sargramostim 125 μg twice daily for 5 days
Trial: 35665035
Drug: Functional acupuncture
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional acupuncture (FA) and routine rehabilitation treatment
Trial: 35665035
Drug: Traditional acupuncture
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional acupuncture (TA) and routine rehabilitation treatment
Trial: 33397663
Drug: Evidence-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based intervention guided by the HEARTS technical package, including training of NCD service providers, provision of essential equipment/supporting materials, and monthly monitoring and feedback.
Trial: 33093013
Drug: Myofunctional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofunctional therapy app
Trial: 35148732
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel (HYAcorp Endogel)
Trial: 35148732
Drug: Ovarian suspension
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian suspension
Trial: 34134794
Drug: L-citrulline (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline (12 g)
Trial: 32711655
Drug: Gold nanomaterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold nanomaterial (GNP) contrast agent used in medical imaging tests
Trial: 35997582
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (qHPV)
Trial: 37356077
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg (single dose)
Trial: 33278016
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 2 weeks (IXE Q2W)
Trial: 33278016
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg every 4 weeks (IXE Q4W)
Trial: 33587431
Drug: Preemptive antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive antiviral therapy (PET)
Trial: 36124667
Drug: Monte Carlo
RxNorm normalized name: Carbo animalis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monte Carlo g-computation
Trial: 36124667
Drug: ICE g-computation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE g-computation
Trial: 33217600
Drug: Thrombin gel
RxNorm normalized name: THROMBIN GELATIN FOAM #10 TOP PAD
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin gel matrix (TGM), Floseal, applied at 5 mL to the pelvic sidewalls after lymphadenectomy
Trial: 35608802
Drug: Primary-site locoregional
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary-site locoregional therapy (PSLT)
Trial: 32211883
Drug: Integrase inhibitor
RxNorm normalized name: Integrase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase inhibitor exposure (ritonavir-boosted darunavir + raltegravir)
Trial: 35613820
Drug: Embedded physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embedded physical therapy intervention
Trial: 32434234
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of topical and intravenous tranexamic acid (TXA)
Trial: 32434234
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) alone
Trial: 32434234
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of IA and IV TXA
Trial: 32434234
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of topical and IV TXA
Trial: 33407156
Drug: Dexmedetomidine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (bolus infusion of 0.5 μg/kg over 10 min, 0.4 μg/kg/h continuous infusion)
Trial: 33407156
Drug: Lidocaine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (bolus infusion of 1.5 mg/kg over 10 min, 1.5 mg/kg/h continuous infusion)
Trial: 33407156
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus Dexmedetomidine (combination of both interventions)
Trial: 34028496
Drug: Antiseizure medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseizure medication (ASM) discontinued at discharge
Trial: 34028496
Drug: Antiseizure medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseizure medication (ASM) maintained at discharge
Trial: 34028496
Drug: Antiseizure medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseizure medication (ASM) discontinued
Trial: 34028496
Drug: Antiseizure medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseizure medication (ASM) maintained
Trial: 33225960
Drug: IFNβ-1a (44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ-1a (44 mcg, three times per week for 2 weeks)
Trial: 35363631
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (BFT)
Trial: 32404343
Drug: Adalimumab taper
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab taper (every 3 weeks) for 36 weeks
Trial: 32580032
Drug: lifestyle plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lifestyle plus metformin
Trial: 35440464
Drug: sintilimab with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab with chemotherapy (cisplatin plus paclitaxel)
Trial: 35440464
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with chemotherapy (cisplatin plus paclitaxel)
Trial: 35440464
Drug: sintilimab with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab with chemotherapy (cisplatin plus 5‐fluorouracil)
Trial: 35440464
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with chemotherapy (cisplatin plus 5‐fluorouracil)
Trial: 33376173
Drug: Pharmacist-led medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medicines management
Trial: 32996172
Drug: Non-surgical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical therapy alone (control)
Trial: 32400354
Drug: Multiyear mass
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiyear mass drug administration (MDA) with praziquantel, provided biannually and/or supplemented by additional interventions.
Trial: 36307187
Drug: NHF 6
RxNorm normalized name: Nifuroxazide
DrugBank: Nifuroxazide (DB13855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHF 6 L/min, FiO2 1.0
Trial: 36307187
Drug: NHF 0
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHF 0 L/min (control)
Trial: 34618744
Drug: Structured neonatal
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured neonatal physical therapy program (SNP), 90 minutes/day, 6 days/week until discharge
Trial: 33297831
Drug: Vinegar drink
RxNorm normalized name: Emergen-C Apple Cider Vinegar Drink Mix Powder for Solution (Apple)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinegar drink (two tablespoons vinegar in a cup of water; 3.6 g acetic acid)
Trial: 33297831
Drug: Commercial vinegar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial vinegar pill (control, 0.045 g acetic acid)
Trial: 38983921
Drug: Sevoflurane-based inhalation
RxNorm normalized name: sevoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane-based inhalation anesthesia
Trial: 32424576
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in urologic therapy
Trial: 32870434
Drug: Arthrocentesis using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis using Shepard's cannula and lactated Ringer's solution
Trial: 32870434
Drug: Glucocorticosteroid (GCS)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroid (GCS) injection using 1 ml/40 mg methylprednisolone acetate
Trial: 35594551
Drug: Everolimus (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (4.5 mg/m2)
Trial: 33901450
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (before disc repositioning)
Trial: 34989159
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg/day) in addition to usual care
Trial: 32066504
Drug: Amantadine sulphate
RxNorm normalized name: Amantadine sulphate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine sulphate (PK‐Merz®; twice 100 mg orally daily)
Trial: 35505326
Drug: Calcium (600
RxNorm normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (600 mg) alone
Trial: 35505326
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (2000 IU per day) combined with Calcium (600 mg)
Trial: 33272643
Drug: Controlled-release pregabalin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release pregabalin (GLA5PR GLARS-NF1 tablets)
Trial: 33272643
Drug: Immediate-release pregabalin
RxNorm normalized name: pregabalin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release pregabalin capsule
Trial: 32500717
Drug: Acamprosate (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (two tablets of 333 mg/d, three times a day)
Trial: 32500717
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets, three times a day)
Trial: 36036644
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS combined with physical therapy
Trial: 36036644
Drug: Cathodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cathodal tDCS combined with physical therapy
Trial: 36036644
Drug: Dual tDCS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual tDCS combined with physical therapy
Trial: 36036644
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS combined with physical therapy
Trial: 34096381
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education and counseling intervention (details on dosage and duration not specified)
Trial: 34606332
Drug: Zoliflodacin 2
RxNorm normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoliflodacin 2 g (therapeutic)
Trial: 34606332
Drug: Zoliflodacin 4
RxNorm normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoliflodacin 4 g (supratherapeutic)
Trial: 34606332
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (positive comparator)
Trial: 35007899
Drug: Peppermint essential
RxNorm normalized name: Nature's Truth Peppermint Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint essential oil inhalation (100% peppermint essential oil, 1 hour duration)
Trial: 34052943
Drug: Conscious sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conscious sedation (CS) with propofol and sufentanil (0.1 mg/kg)